| Identification | Back Directory | [Name]
Benzamide, 3-[3-ethyl-5-(4-methoxyphenyl)-1H-1,2,4-triazol-1-yl]-N-(4-phenylbutyl)- | [CAS]
2093946-08-6 | [Synonyms]
Benzamide, 3-[3-ethyl-5-(4-methoxyphenyl)-1H-1,2,4-triazol-1-yl]-N-(4-phenylbutyl)- | [Molecular Formula]
C28H30N4O2 | [MOL File]
2093946-08-6.mol | [Molecular Weight]
454.56 |
| Hazard Information | Back Directory | [Description]
YQ456 is a novel potent and selective inhibitor of myoferlin (MYOF inhibitor), which attenuates colorectal cancer progression. YQ456 showed high binding affinity to MYOF (KD = 37 nM) and excellent anti-invasion capability (IC50 = 110 nM). YQ456 was reported for the first time to interfere with the interactions between MYOF and Ras-associated binding (Rab) proteins at low nanomolar levels. This interference disrupted several vesicle trafficking processes, including lysosomal degradation, exosome secretion, and mitochondrial dynamics. Further, YQ456 exhibited excellent inhibitory effects on the growth and invasiveness of colorectal cancer. As the first attempt, the anticancer efficacy of YQ456 in the patient-derived xenograft (PDX) mouse model indicated that targeting MYOF may serve as a novel and practical therapeutic approach for colorectal cancer. | [Uses]
YQ456 is a novel small molecule inhibitor of myoferlin that showed high binding affinity to myoferlin with a KD of 37 nM and excellent anti-invasion capability with an IC50 of 110 nM. | [IC 50]
MYOF: 110 nM (IC50) | [References]
[1] He Y, et al. A potent and selective small molecule inhibitor of myoferlin attenuates colorectal cancer progression. Clin Transl Med. 2021 Feb;11(2):e289. DOI:10.1002/ctm2.289 |
|
|